Neffy, an epinephrine nasal spray designed to reduce severe allergic reactions and serve as an alternative to EpiPens, has received FDA approval, ARS Pharmaceuticals announced today in a press release.
The FDA stated that the nasal spray is the first needle-free emergency treatment for potentially fatal allergic reactions. Dr. Kelly Stone, from the FDA’s Center for Drug Evaluation and Research, mentioned that Neffy could help in the rapid treatment of anaphylaxis, providing an important option for addressing this critical need.
Neffy has been approved to treat Type I Allergic Reactions in adults and children over 66 pounds, including anaphylaxis. This life-threatening reaction must be promptly treated with epinephrine and a visit to the emergency room.
Previously, EpiPens were the main treatment option, but many found the needle injections daunting. Neffy’s approval offers a needle-free option to address this issue, as highlighted by ARS Pharmaceuticals’ CEO, Richard Lowenthal.
ARS Pharmaceuticals
Research has shown EpiPen underuse due to various reasons, leading to the need for alternatives like Neffy, which is seen as more convenient and less intimidating to use, particularly for children.
Neffy’s approval journey involved FDA scrutiny and studies, ultimately leading to its availability within eight weeks with plans for child usage approval in the future.
Before you go, check out these cold-relieving products for your child:
